

**Date and Time:** 27<sup>th</sup> June 2013 10:00-16:00

**Minutes:** Confirmed

**Multiple Sclerosis GDG Meeting 8**

**Place:** Boardroom, National Clinical Guideline Centre, 180 Great Portland Street,  
London, W1W 5QZ

**Present:** GDG

1. Paul Cooper	PC
2. Jeremy Chataway	JC
3. Peter Brex	PB
4. Wendy Hendrie	WH
5. Susan Hourihan	SH
6. Noreen Barker	NB
7. Richard Warner	RW
8. Aleks de Gromoboy	ADG
9. Ann Hodgson	AH
10. Emma Rowe	ER
11. Paul Riordan-Eva	PRE

NCGC Technical team

12. Sharon Swain	SS
13. Mark Perry	MP
14. Amy Kelsey	AK
15. Sophia Winterbourne	SW
16. Krishna Chinthapalli	KC
17. Gill Ritchie	GR

NICE:

1. Caroline Keir	CK
------------------	----

Apologies

1. Norma O'Flynn	NOF
2. David Kernick	DK
3. Pamela Bostock	PB

## Notes

1. The Chair welcomed the group to the Multiple Sclerosis Guideline Development Group (GDG) meeting 8. Apologies were received from Norma O'Flynn, Pam Bostock and David Kernick. The Chair introduced Caroline Keir, NICE Guideline Commissioning Manager and Paul Riordan-Eva, a co-opted neuro-ophthalmology expert.

2. The Chair asked the GDG to declare any personal specific, personal non-specific, non-personal specific or non-personal non-specific interests

All GDG members had no change in their previous declarations.

3. The Chair introduced Sharon Swain, NCGC Senior Research Fellow, who discussed evidence statements and clinical summary tables with the GDG. The Chair thanked SS for her presentation.

4. The Chair introduced Paul Riordan-Eva, Consultant Ophthalmologist from Kings College Hospital, and co-opted ophthalmology expert, who gave a presented an introduction to oscillopsia. The Chair thanked PRE for his presentation.

5. The Chair introduced Mark Perry, NCGC Research Fellow, who presented the clinical evidence review of the pharmacological treatment of oscillopsia for adults with MS and their carers. The GDG discussed the evidence presented. The Chair thanked MP for his presentation.

6. The Chair introduced Sophia Winterbourne, NCGC Health Economist, who presented the health economic evidence review of the pharmacological treatment of oscillopsia for adults with MS and their carers. The GDG discussed the evidence presented and developed draft recommendations. The Chair thanked SW for her presentation.

7. SW then presented an update from the coordination of care evidence review. The Chair thanked SW for her presentation.

8. MP then presented the clinical evidence review of non-pharmacological management with complementary and alternative therapies for adults with MS and their carers. The GDG discussed the evidence presented. The Chair thanked MP for his presentation.

9. SW then presented the health economic evidence review of non-pharmacological management with complementary and alternative therapies for adults with MS and their carers. The GDG discussed the evidence presented and developed draft recommendations. The Chair thanked SW for her presentation.

10. SW then presented an update on the spasticity evidence review to the GDG. The Chair thanked SW for her presentation.

11. SS then led discussion with the GDG on the research protocol for 1 clinical question. The following research protocol was discussed and by the group:

- For adults with MS, what is the clinical evidence and cost effectiveness of the non-pharmacological management of memory and cognitive problems with neuropsychological rehabilitation?

## **Notes**

12. There was no AOB. The Chair closed the meeting and thanked everyone for attending.

## **Date, time and venue of the next meeting**

13. 6<sup>th</sup> September 2013, 10:00-16:00, Boardroom, National Clinical Guideline Centre, 180 Great Portland Street, London, W1W 5QZ